Twist Bioscience Corp (TWST): R&D Expense
$80.28M
Year ended 2025-09-30
$71.86M
Trailing 12 months to 2026-06-30
-12.6%
3-year compound annual growth
+13.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $80.28M | -11.6% | 2025-11-17, From 2024-10-01 |
| 2024-09-30 | $90.85M | -15.0% | 2025-11-17, From 2023-10-01 |
| 2023-09-30 | $106.89M | -11.1% | 2025-11-17, From 2022-10-01 |
| 2022-09-30 | $120.31M | +74.2% | 2024-11-18, From 2021-10-01 |
| 2021-09-30 | $69.07M | +60.6% | 2023-11-21, From 2020-10-01 |
| 2020-09-30 | $43.01M | +20.5% | 2023-06-05, From 2019-10-01 |
| 2019-09-30 | $35.68M | +75.4% | 2021-11-23, From 2018-10-01 |
| 2018-09-30 | $20.35M | +6.1% | 2020-11-27, From 2017-10-01 |
| 2017-09-30 | $19.17M | n/a | 2019-12-13, From 2016-10-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | 2025-09-30 | $80.28M | -11.6% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $58.05M | +8.3% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $274.87M | +23.7% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $64.32M | +20.5% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $4.76M | +162.7% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $93.77M | -8.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $27.56M | +11.2% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $300.27M | +8.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
Compare TWST, KRYS, IMCR, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗